---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-044706"
form_type: "8-K"
ticker: "VTRS"
cik: "0001792044"
company_name: "Viatris Inc"
filed_at: "2025-12-08T23:59:59+00:00"
generated_at: "2026-05-16T14:02:02.667690+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viatris to sell Biocon Biologics stake for $815M in cash and equity from Biocon Limited

## Summary
- Viatris receives $400M cash and $415M in newly issued Biocon Ltd shares for Biocon Biologics convertible preferred equity.
- Biosimilars non-compete restrictions end immediately ex-U.S., by Nov 2026 in U.S., accelerating Viatris' market access.
- Transaction expected to close in Q1 2026; subject to closing conditions and taxes; Citi acted as financial advisor.
- CEO Scott A. Smith says deal provides significant optionality and advances Viatris' strategic evolution.
- Biocon shares subject to six-month lock-up; consideration subject to related taxes.

## SEC filing metadata
- accession: 0001140361-25-044706
- form_type: 8-K
- ticker: VTRS
- cik: 0001792044
- company_name: Viatris Inc
- filed_at: 2025-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1792044/000114036125044706/0001140361-25-044706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1792044/000114036125044706/ef20060770_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-044706
- JSON: https://secwatch.observer/filing/0001140361-25-044706.json
- Plain text: https://secwatch.observer/filing/0001140361-25-044706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.